Enliven Therapeutics, Inc.
ELVN
$58.82
$0.761.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.26M | 34.14M | 33.80M | 26.93M | 25.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 124.41M | 115.79M | 119.66M | 112.27M | 114.24M |
| Operating Income | -124.41M | -115.79M | -119.66M | -112.27M | -114.24M |
| Income Before Tax | -105.93M | -98.78M | -103.69M | -97.21M | -100.22M |
| Income Tax Expenses | -- | -- | -- | 0.00 | 0.00 |
| Earnings from Continuing Operations | -105.93 | -98.78 | -103.69 | -97.21 | -100.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.93M | -98.78M | -103.69M | -97.21M | -100.22M |
| EBIT | -124.41M | -115.79M | -119.66M | -112.27M | -114.24M |
| EBITDA | -124.28M | -115.59M | -119.40M | -111.97M | -113.93M |
| EPS Basic | -1.67 | -1.66 | -1.86 | -1.85 | -2.00 |
| Normalized Basic EPS | -1.04 | -1.04 | -1.16 | -1.15 | -1.25 |
| EPS Diluted | -1.67 | -1.66 | -1.86 | -1.85 | -2.00 |
| Normalized Diluted EPS | -1.04 | -1.04 | -1.16 | -1.15 | -1.25 |
| Average Basic Shares Outstanding | 253.28M | 239.21M | 226.46M | 214.11M | 200.28M |
| Average Diluted Shares Outstanding | 253.28M | 239.21M | 226.46M | 214.11M | 200.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |